Cite
Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide.
MLA
Kawahara, Takashi, et al. “Development and Validation of a Survival Nomogram and Calculator for Male Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate and/or Enzalutamide.” BMC Cancer, vol. 23, no. 1, Mar. 2023, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s12885-023-10700-0.
APA
Kawahara, T., Saigusa, Y., Yoneyama, S., Kato, M., Kojima, I., Yamada, H., Kamihira, O., Tabata, K., Tsumura, H., Iwamura, M., Makiyama, K., Uemura, H., & Miyoshi, Y. (2023). Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer, 23(1), 1–8. https://doi.org/10.1186/s12885-023-10700-0
Chicago
Kawahara, Takashi, Yusuke Saigusa, Shuko Yoneyama, Masashi Kato, Ippei Kojima, Hiroshi Yamada, Osamu Kamihira, et al. 2023. “Development and Validation of a Survival Nomogram and Calculator for Male Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate and/or Enzalutamide.” BMC Cancer 23 (1): 1–8. doi:10.1186/s12885-023-10700-0.